13F Pro quality score
Rank #2,524 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
Biofrontera Inc. (BFRI) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BFRI at 28.5/100 on a composite quality score built from its SEC filings, placing it at rank #2,524 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include earnings quality (5.5) and balance sheet strength (8.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 36.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Biofrontera Inc. reports quarterly revenue of $12.0M, net income of $-604.0K, an operating margin of -4.4%. Top institutional holders of BFRI by reported 13-F value include Rosalind Advisors, AIGH Capital Management, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. BFRI trades on the Nasdaq exchange and files with the SEC under CIK 1858685. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BFRI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Biofrontera Inc. directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 1858685 →